Benzinga | Nov 3, 2021 09:13AM EDT

Raymond James Downgrades Exact Sciences to Outperform, Lowers Price Target to $130

Raymond James analyst Andrew Cooper downgrades Exact Sciences (NASDAQ:EXAS) from Strong Buy to Outperform and lowers the price target from $160 to $130.